fbpx Skip to main content

FRIDAY, Aug. 28, 2020 (HealthDay News) — The risk for cancer is reduced among patients with multiple sclerosis (MS), according to a systematic review and meta-analysis published online Aug. 13 in Autoimmunity Reviews.

Mahsa Ghajarzadeh, M.D., M.P.H., from the Tehran University of Medical Sciences in Iran, and colleagues examined the pooled risk for cancer in patients with MS. Data were included from five articles that met the inclusion criteria.

The researchers found that in the included articles, the risk ratio was estimated between 0.7 and 1.67, with the pooled risk ratio estimated at 0.83. In two studies, the pooled prevalence of breast cancer was 2 percent; in two studies, the pooled prevalence of digestive cancer was 2 percent; and in two studies, the pooled prevalence of skin cancer was 1 percent.

“To the best of our knowledge, this is the first study evaluating the risk of cancer in patients with MS,” the authors write. “The result of this systematic review showed that the risk of cancer in patients with MS is less than the general population.”

Abstract/Full Text (subscription or payment may be required)

You May Also Like::  Oxidative Stress, Biomarkers, and Potential Therapeutic Approaches in Alopecia Areata

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More